https://mindmedicinelaw.com/briefing/mdma-therapy-s-impact-on-discrimination-trauma-symptoms-20260711-21275The Psychedelic Journalen2026-07-12T15:05:02.603472+00:00MDMA Therapy's Impact on Discrimination Trauma SymptomsMDMA-assisted therapy, discrimination trauma, psychedelic research, culturally-informed treatment, clinical trials, mental health policy, marginalized populations, posttraumatic stress disorder, psychotherapy, public healthhttps://mindmedicinelaw.com/briefing/propofol-ketamine-vs-propofol-fentanyl-in-d-c-anesthesia-20260711-21291The Psychedelic Journalen2026-07-12T15:04:53.291751+00:00Propofol-Ketamine vs. Propofol-Fentanyl in D&C Anesthesiapropofol-ketamine, propofol-fentanyl, hemodynamic stability, Dilatation and Curettage, anesthesia, peri-operative complications, analgesia, clinical trials, anesthetic practices, ketaminehttps://mindmedicinelaw.com/briefing/doj-faces-scrutiny-over-halt-fentanyl-act-deadline-20260711-21211The Psychedelic Journalen2026-07-11T22:04:44.510510+00:00DOJ Faces Scrutiny Over HALT Fentanyl Act DeadlineHALT Fentanyl Act, DOJ delay, drug scheduling, fentanyl analogues, regulatory clarity, drug policy, research implications, enforcement priorities, controlled substances, policy impacthttps://mindmedicinelaw.com/briefing/comp360-psilocybin-in-depression-clinical-insights-and-implications-20260711-21209The Psychedelic Journalen2026-07-11T22:04:36.506850+00:00COMP360 Psilocybin in Depression: Clinical Insights and ImplicationsCOMP360 psilocybin, treatment-resistant depression, psychedelic therapy, clinical trials, mental health treatment, neuroplasticity, FDA approval, psychiatric research, regulatory implications, ethical considerationshttps://mindmedicinelaw.com/briefing/personality-shifts-in-german-students-post-psychedelic-use-20260710-21098The Psychedelic Journalen2026-07-12T22:04:04.010317+00:00Personality Shifts in German Students Post-Psychedelic Usepsychedelic research, personality changes, German students, Openness, Conscientiousness, non-clinical settings, Big Five Inventory, Berlin college students, psychedelic use, neurosciencehttps://mindmedicinelaw.com/briefing/anesthetic-agents-influence-ect-seizure-duration-and-cognition-20260710-21145The Psychedelic Journalen2026-07-12T22:03:56.264639+00:00Anesthetic Agents Influence ECT Seizure Duration and Cognitionelectroconvulsive therapy, anesthetic agents, seizure duration, cognitive recovery, etomidate, ketamine, propofol, randomized controlled trials, mental health treatment, evidence-based guidelineshttps://mindmedicinelaw.com/briefing/future-drug-targets-in-depression-treatment-emerging-therapies-20260710-21146The Psychedelic Journalen2026-07-12T22:03:48.366919+00:00Future Drug Targets in Depression Treatment: Emerging Therapiesdepression treatment, NMDA receptor modulators, pharmacogenomics, personalized medicine, rapid-acting antidepressants, glutamatergic dysfunction, neuroinflammation, brain-derived neurotrophic factor, artificial intelligence in drug discovery, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/digital-technologies-and-altered-states-a-new-frontier-20260710-21097The Psychedelic Journalen2026-07-12T22:03:41.771199+00:00Digital Technologies and Altered States: A New Frontierdigital technologies, altered states of consciousness, virtual reality, biofeedback, artificial intelligence, digital therapeutics, psychophysiological effects, clinical applications, market opportunities, mental healthhttps://mindmedicinelaw.com/briefing/spontaneous-recovery-in-fear-conditioning-implications-for-ptsd-20260710-21276The Psychedelic Journalen2026-07-12T22:03:32.055514+00:00Spontaneous Recovery in Fear Conditioning: Implications for PTSDspontaneous recovery, fear conditioning, PTSD treatment, anxiety relapse, pharmacological interventions, non-pharmacological methods, exposure therapy, clinical trials, neuroscience research, mental health policyhttps://mindmedicinelaw.com/briefing/new-voluntary-fentanyl-intake-model-in-mice-shows-dependence-20260710-21302The Psychedelic Journalen2026-07-12T15:05:33.495319+00:00New Voluntary Fentanyl Intake Model in Mice Shows Dependencevoluntary fentanyl intake, opioid dependence model, dose-dependent withdrawal, sex differences in addiction, opioid crisis research, preclinical opioid model, naloxone-precipitated withdrawal, mice opioid studies, opioid addiction mechanisms, public health strategieshttps://mindmedicinelaw.com/briefing/epigenetic-impacts-of-psychedelics-and-ketamine-in-neuromodulation-20260710-21314The Psychedelic Journalen2026-07-12T15:05:24.971621+00:00Epigenetic Impacts of Psychedelics and Ketamine in Neuromodulationepigenetic changes, psychedelics, ketamine, neuromodulation, clinical trials, mental healthhttps://mindmedicinelaw.com/briefing/gdnf-overexpression-alters-temperament-in-rats-implications-for-psychiatric-trea-20260710-21259The Psychedelic Journalen2026-07-12T15:05:11.296524+00:00GDNF Overexpression Alters Temperament in Rats: Implications for Psychiatric TreatmentGDNF, temperament, psychiatric disorders, neurotrophic factors, dopamine transporter, serotonin neurotransmission, animal models, neuroscience, treatment development, clinical trialshttps://mindmedicinelaw.com/briefing/innovations-in-psychedelic-therapeutics-5-ht2a-and-aerosol-delivery-20260710-21315The Psychedelic Journalen2026-07-12T15:04:44.080141+00:00Innovations in Psychedelic Therapeutics: 5-HT2A and Aerosol Deliverypsychedelic therapeutics, 5-HT2A receptor, aerosol delivery, 5-MeO-DMT, neuropsychiatric treatment, serotonergic medicine, clinical trials, drug delivery systems, psychedelic research, mental healthhttps://mindmedicinelaw.com/briefing/psychedelics-enhance-reward-responsiveness-in-rats-20260710-21133The Psychedelic Journalen2026-07-11T22:05:01.782478+00:00Psychedelics Enhance Reward Responsiveness in Ratspsychedelics, reward responsiveness, anhedonia, psilocybin, ketamine, 5-HT 2A receptor, preclinical study, psychiatric disorders, clinical trials, neurosciencehttps://mindmedicinelaw.com/briefing/future-drug-targets-for-depression-emerging-therapies-20260710-21144The Psychedelic Journalen2026-07-11T22:04:53.356392+00:00Future Drug Targets for Depression: Emerging Therapiesdepression treatment, precision medicine, rapid-acting therapies, ketamine, clinical trials, pharmacogenomics, personalized medicine, novel antidepressants, NMDA receptor modulators, psychiatric disordershttps://mindmedicinelaw.com/briefing/psychedelic-assisted-psychosexual-therapy-emerging-frontiers-20260710-21118The Psychedelic Journalen2026-07-11T22:04:17.373497+00:00Psychedelic-Assisted Psychosexual Therapy: Emerging Frontierspsychedelic-assisted therapy, psychosexual dysfunction, psilocybin, MDMA, clinical trials, mental health, altered states of consciousness, therapeutic landscapes, policy implications, empathogenic agentshttps://mindmedicinelaw.com/briefing/digital-tool-enhances-alzheimer-s-therapy-eligibility-assessment-20260709-21317The Psychedelic Journalen2026-07-12T22:04:12.770878+00:00Digital Tool Enhances Alzheimer's Therapy Eligibility Assessmentdigital cognitive assessment, MMSE scores, Alzheimer's therapy, health disparities, machine learning, Bio-Hermes-001 study, DCR tool, healthcare policy, digital triage, data privacyhttps://mindmedicinelaw.com/briefing/dmt-s-impact-on-human-neural-stem-cells-mechanisms-and-implications-20260709-21099The Psychedelic Journalen2026-07-11T22:04:26.831957+00:00DMT's Impact on Human Neural Stem Cells: Mechanisms and ImplicationsDMT, neural stem cells, neurogenesis, psychedelic research, antidepressant effects, neurotrophins, clinical applications, neural plasticity, mental health treatment, psychedelic therapyhttps://mindmedicinelaw.com/briefing/bayesian-framework-for-well-being-neuroscience-insights-20260709-20663The Psychedelic Journalen2026-07-11T15:04:18.289569+00:00Bayesian Framework for Well-being: Neuroscience Insightsbayesian framework, well-being, psychedelic research, neuroscience, psychological health, predictive regulation, homeostasis, allostasis, affective states, clinical psychologyhttps://mindmedicinelaw.com/briefing/new-protocol-for-iv-ketamine-in-depression-treatment-20260709-20675The Psychedelic Journalen2026-07-11T15:04:09.702964+00:00New Protocol for IV Ketamine in Depression Treatmentintravenous ketamine, treatment-resistant depression, depression treatment, ketamine protocol, patient monitoring, psychiatric carehttps://mindmedicinelaw.com/briefing/neural-dynamics-in-mbct-for-depression-a-new-framework-20260708-20629The Psychedelic Journalen2026-07-11T15:04:42.105581+00:00Neural Dynamics in MBCT for Depression: A New Frameworkmindfulness-based cognitive therapy, major depressive disorder, complex harmonics decomposition, neural dynamics, fMRI, ruminative thinking, brain flexibility, psychiatric treatment, neuroimaging, mental health interventionshttps://mindmedicinelaw.com/briefing/behavioral-impact-on-rat-eeg-in-psychedelic-drug-studies-20260708-20630The Psychedelic Journalen2026-07-11T15:04:31.392485+00:00Behavioral Impact on Rat EEG in Psychedelic Drug Studiesbehavioral activity, EEG outcomes, psychedelic research, preclinical studies, standardization, neurophysiology, Wistar rats, EEG power spectrum, global functional connectivity, neuroactive substanceshttps://mindmedicinelaw.com/briefing/psychotropic-drug-research-challenges-in-germany-regulatory-hurdles-20260706-20030The Psychedelic Journalen2026-07-11T15:05:06.055413+00:00Psychotropic Drug Research Challenges in Germany: Regulatory Hurdlespsychotropic drugs, Germany, regulatory hurdles, platform studies, mental illness complexity, Federal Joint Committee, drug approval process, precision psychiatry, clinical trials, pharmaceutical industryhttps://mindmedicinelaw.com/briefing/intravenous-ketamine-in-psychiatry-efficacy-and-challenges-20260706-20365The Psychedelic Journalen2026-07-11T15:04:57.378372+00:00Intravenous Ketamine in Psychiatry: Efficacy and Challengesintravenous esketamine, treatment-resistant depression, NMDA receptor antagonist, psychiatric treatment, adverse effects, standardized protocols, neuroplasticity, rapid antidepressant